ropinirole has been researched along with Bradykinesia in 1 studies
Excerpt | Relevance | Reference |
---|---|---|
"Ropinirole was weakly neuroprotective in this model." | 1.32 | S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole. ( Brocco, M; Brotchie, J; Crossman, A; Di Cara, B; Gobert, A; Hill, M; Jackson, M; Jenner, P; Joyce, JN; McGuire, S; Millan, MJ; Peglion, JL; Smith, L, 2004) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Millan, MJ | 1 |
Di Cara, B | 1 |
Hill, M | 1 |
Jackson, M | 1 |
Joyce, JN | 1 |
Brotchie, J | 1 |
McGuire, S | 1 |
Crossman, A | 1 |
Smith, L | 1 |
Jenner, P | 1 |
Gobert, A | 1 |
Peglion, JL | 1 |
Brocco, M | 1 |
1 other study available for ropinirole and Bradykinesia
Article | Year |
---|---|
S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.
Topics: Acetylcholine; Animals; Callithrix; Cells, Cultured; Disease Models, Animal; Dopamine Agonists; Dopa | 2004 |